Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Diversifies With $7.2B Receptos Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene sees Receptos' ozanimod as a potential best-in-class drug for MS and inflammatory diseases like ulcerative colitis, largely because the S1P receptor modulator appears to have a lower CV and liver risk than other therapies in the class.


Related Content

Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts